Anti-inflammatory treatments in microbial keratitis.

Area of Science:

• Ophthalmology
• Infectious Diseases
• Immunology

Background:

• Infectious keratitis is a major global cause of corneal blindness.
• The use of anti-inflammatory agents, particularly corticosteroids, in infectious keratitis management is debated.
• Evidence supporting anti-inflammatory use varies significantly with the causative pathogen.

Purpose of the Study:

• To review current evidence on topical anti-inflammatory therapies for infectious keratitis.
• To analyze the role of corticosteroids, calcineurin inhibitors, and other agents in bacterial, fungal, and amoebic keratitis.
• To identify knowledge gaps and the need for evidence-based treatment protocols.

Main Methods:

• Systematic review of existing literature on anti-inflammatory use in infectious keratitis.
• Analysis of data from randomized controlled trials, case reports, and preclinical studies.
• Focus on bacterial, fungal, and amoebic keratitis treatment strategies.

Main Results:

• Corticosteroid benefits in infectious keratitis are organism-dependent, with some support in bacterial keratitis but weak evidence for fungal or amoebic forms.
• Steroids are generally avoided in fungal keratitis and used cautiously in amoebic keratitis.
• Steroid-sparing agents like calcineurin inhibitors may benefit fungal keratitis; emerging therapies show promise but lack robust data.

Conclusions:

• Judicious use of anti-inflammatory agents can be beneficial in infectious keratitis, but optimal strategies remain unclear.
• Robust human data and large trials are needed to establish evidence-based treatment protocols.
• Balancing infection control with inflammation management is crucial for effective infectious keratitis treatment.